diclofenac has been researched along with Myofascial Pain Syndromes in 7 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Myofascial Pain Syndromes: Muscular pain in numerous body regions that can be reproduced by pressure on TRIGGER POINTS, localized hardenings in skeletal muscle tissue. Pain is referred to a location distant from the trigger points. A prime example is the TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-four patients with localized myofascial pain were treated with injections, 11 with 2 ml lidocaine 1% and 13 with 2 ml diclofenac (Voltaren) (50 mg) given in the trigger-point." | 9.06 | Diclofenac versus lidocaine as injection therapy in myofascial pain. ( Frost, A, 1986) |
| "Dry needling on latent and active MTrPs combined with stretching and oral diclofenac combined with stretching can effectively relieve pain, improve function, and restore knee ROM affected by KOA." | 5.69 | Dry needling on latent and active myofascial trigger points versus oral diclofenac in patients with knee osteoarthritis: a randomized controlled trial. ( Dong, YL; Huang, QM; Ma, YT; Wang, B; Xie, WP; Zheng, YJ, 2023) |
| "Twenty-four patients with localized myofascial pain were treated with injections, 11 with 2 ml lidocaine 1% and 13 with 2 ml diclofenac (Voltaren) (50 mg) given in the trigger-point." | 5.06 | Diclofenac versus lidocaine as injection therapy in myofascial pain. ( Frost, A, 1986) |
| " Visual analog scale (VAS), cervical active range of motion, pressure pain threshold of the myofascial trigger point (MTrP), patient global assessment, Neck Disability Index, and the occurrence of adverse events were assessed on Day 0 (baseline), Day 4, and Day 8." | 2.75 | Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius. ( Chen, CC; Chern, SH; Hong, CZ; Hsieh, LF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, YT | 1 |
| Dong, YL | 1 |
| Wang, B | 1 |
| Xie, WP | 1 |
| Huang, QM | 1 |
| Zheng, YJ | 1 |
| Takla, MKN | 1 |
| Rezk-Allah, SS | 1 |
| Lee, J | 1 |
| Burke, DT | 1 |
| Hsieh, LF | 1 |
| Hong, CZ | 1 |
| Chern, SH | 1 |
| Chen, CC | 1 |
| Kapoor, S | 1 |
| Frost, A | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Placebo-controlled Crossover Trial Evaluating Topical Lidocaine Patch(es) for Mechanical Neck Pain.[NCT04378959] | 76 participants (Actual) | Interventional | 2021-02-01 | Completed | |||
| Double-blind, Prospective Comparison of Medications Used in Trigger Point Injections - Ketorolac, Lidocaine, or Dexamethasone[NCT03028012] | Phase 4 | 10 participants (Actual) | Interventional | 2017-05-02 | Terminated (stopped due to Poor enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants in this study underwent TPIs by the following method. The needle was inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. This was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain, one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Post Injections Up to Three Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac | 1 |
| Lidocaine | 0 |
| Dexamethasone | 0 |
The BPI was evaluated on a scale from 0-10. Zero would mean no interference and 10 would be calculated at complete interferences. We used a 7-point questionnaire about pain. All scores were calculated at baseline and three months. (NCT03028012)
Timeframe: Baseline and Three Months
| Intervention | score on a scale (Number) | |||
|---|---|---|---|---|
| Participant Number #3 at Baseline | Participant Number #3 at 3 Months | Participant Number #8 at Baseline | Participant #8 at 3 Months | |
| Ketorolac | 8 | 3 | 5 | 3 |
TPI were treated with a needle inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. Such was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain,one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Injection and Three Month Post Injection(s)
| Intervention | score on a scale (Number) | |||
|---|---|---|---|---|
| Participant Number 3 at Baseline | Participant Number 3 at 3 Months | Participant Number 8 at Baseline | Participant Number 8 at 3 Months | |
| Ketorolac | 8 | 3 | 5 | 3 |
5 trials available for diclofenac and Myofascial Pain Syndromes
| Article | Year |
|---|---|
Dry needling on latent and active myofascial trigger points versus oral diclofenac in patients with knee osteoarthritis: a randomized controlled trial.
Topics: Diclofenac; Dry Needling; Humans; Myofascial Pain Syndromes; Osteoarthritis, Knee; Pain; Trigger Poi | 2023 |
Immediate Effects of Simultaneous Application of Transcutaneous Electrical Nerve Stimulation and Ultrasound Phonophoresis on Active Myofascial Trigger Points: A Randomized Controlled Trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Diclofenac; Female; Human | 2018 |
Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; | 2010 |
[Diclofenac compared with lidocaine in the treatment of myofascial pain by injections].
Topics: Clinical Trials as Topic; Diclofenac; Female; Humans; Injections, Intramuscular; Lidocaine; Male; My | 1986 |
Diclofenac versus lidocaine as injection therapy in myofascial pain.
Topics: Diclofenac; Female; Humans; Injections, Intramuscular; Lidocaine; Male; Middle Aged; Myofascial Pain | 1986 |
2 other studies available for diclofenac and Myofascial Pain Syndromes
| Article | Year |
|---|---|
Lower gastrointestinal bleeding associated with diclofenac topical patch in a patient with colonic mass and on antiplatelet therapy for atrial fibrillation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Clopidogrel; Colonic Neoplasms; | 2014 |
Diclofenac patch: clinical applications beyond pain control.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Myofascial P | 2010 |